What Are the Stages of Sleep
Semaglutide (Wegovy) FDA-approved for: Chronic weight management Treatment of Metabolic dysfunction-Associated Steatohepatitis (MASH) approved August 2025 FDA-indicated for: Reducing risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease who are obese or overweight Weekly injection Clinical trials show an average weight loss of 1215% of body weight
Jump to: Evidence from clinical trials | How weight loss changes with dose | Individual factors affecting results | Side effects at different doses | How to find your ideal Wegovy dose | Frequently asked questions | Take home message Higher doses of Wegovy (semaglutide) lead to greater average weight loss, but the increase gets smaller with each dose increase
According to the Summary of Product Characteristics (SmPC), nausea occurs in approximately 20% of patients taking semaglutide (Ozempic), up to 21% with dulaglutide (Trulicity), and 20-40% with liraglutide (Saxenda), depending on dose
however, it can vary widely among different people depending on age, gender, mental state and physical health
Regular use of an infrared sauna can enhance your circulation and improve blood vessel function, which might lead to lower blood pressure and a reduced risk of heart disease*
